[Click eStock] "JW Saengmyeong Science Target Price 15,000 Won... 6.3%↓"

On the 30th, Kiwoom Securities set the target price for JW Life Science at 15,000 KRW, which is 6.3% lower than the previous figure.

Although concerns about sales of infusion solutions remain high due to the ongoing medical strike, the sales trends of major infusion solution companies indicate that the impact is limited. In this situation, factories continue to operate steadily, producing infusion products, and smooth deliveries to its affiliate JW Choongwae Pharmaceutical are ongoing. Additionally, by expanding its B2B (business-to-business) operations, sales channels to companies other than affiliates are diversifying.

In October last year, the TPN (Total Parenteral Nutrition) factory in Dangjin, Chungnam, increased its production capacity by 37%, securing the ability to manufacture 14 million nutrition infusions annually. It is positive that more nutrition infusions, which are mainly used in hospitals and clinics less affected by the medical strike rather than large hospitals, can be produced.

Furthermore, in June last year, JW Choongwae Pharmaceutical's TPN product 'Winnerf A Plus Injection' received approval from the Ministry of Food and Drug Safety. The official launch process was completed in January this year, and it is now distributed in the market, so related production volume is expected to increase.

Minsoo Shin, a researcher at Kiwoom Securities, said, "By utilizing the increased production capacity to cover fixed costs and not adopting a policy of significantly increasing selling and administrative expenses compared to before, profit margins can gradually improve."

Annual performance is forecasted with sales of 223.9 billion KRW and operating profit of 33.6 billion KRW. For next year, sales of 240 billion KRW and operating profit of 36.9 billion KRW are projected.